Neal D. Shore, MD, on the Importance of Multidisciplinary Care in Advanced Prostate Cancer

Video

Neal D. Shore, MD, FACS, discusses the importance of multidisciplinary care for patients with advanced prostate cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Neal D. Shore, MD, FACS, regarding the importance of multidisciplinary care for patients with advanced prostate cancer.

Incorporating a multidisciplinary approach for patients with advanced prostate cancer is essential in order to provide patients with further therapeutic benefit and improve quality of life.

Transcript:

When we are taking care of our patients with advanced cancers, and advanced prostate cancer is no exception, fatigue and the spectrum of neurocognitive maladies, as well as cardio-oncologic maladies become that much more important. All across the field of cancer in its totality, [we] are recognizing this. [By] incorporating a multidisciplinary approach, either as the [urologic] oncologist, the medical oncologist, the radiation oncologist, the nuclear medicine radiologist, or the pathologist—whoever is really involved in the care of the patient—appreciating that the spectrum of cardio-oncologic and neuro-oncologic differences in drugs of the same therapeutic class need to be studied [is important]. It may not affect all patients, it may not affect most patients, but there [are] clearly going to be certain patients or a significant population of patients [for whom] the right drug selection and comparable therapeutic mechanism of action classes could really benefit a patient and help their quality of life.

Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Related Content